Goodwin

Partner

Duncan Greenhalgh is a senior partner in Goodwin's nationally recognized Life Sciences group where he counsels companies, entrepreneurs, investors, and investment banks on intellectual property matters. His practice focuses on developing and implementing complex intellectual property and market exclusivity strategies for emerging and mature life sciences companies, with a focus on maximizing exclusivity for biologic and chemical therapeutics. He also advises clients on intellectual property due diligences, freedom-to-operate and risk assessments, and intellectual property agreements, including collaboration and license agreements.

Dr. Greenhalgh has been consistently recognized as a leading life science patent attorney by numerous legal guides. Chambers USA recognized him for being “particularly adept at advising life sciences companies on IP and market strategy” and noted that he is “great at finding solutions and has good business acumen.”

Dr. Greenhalgh has been recognized by Chambers USA: America’s Leading Lawyers for Business (2009-2024), LMG Life Sciences (2012-2014, 2016-2024), Managing IP - IP Stars (2012-2025), The Best Lawyers in America (2017-2024) and Intellectual Asset Management’s Patent 1000 (2015-2024) as an industry leader for his intellectual property expertise in life sciences.

J.D., 1998, Suffolk University School of Law (magna cum laude) PhD, Biochemistry, 1989 University of Leeds, BSc, Biotechnology, 1985 University of Leeds (with honors)